Fluorescent Universal Human IgG/IgM Lateral Flow Serology Kit (Quantum Dots)
Facebook
X
Pinterest
Email
Antibody tests are a method of choice to determine if a person has been exposed to a pathogen or not. They are also incredibly valuable in the detection of autoantibodies that can be found in human autoimmune disorders. In this test, a biotinylated antigen (User supplied) is mixed with a biotinylated rabbit IgG (bind to goat anti rabbit control line) and sample (human sera or plasma) is simply mixed into with the specially designed assay running buffer in a well of the supplied 96-well plate, mixed and is then added to the sample port of the cassette. Generally, the reaction is complete in 10-15 minutes. It is very important to note that the relative stoichiometry between the biotinylated antigen, biotinylated rabbit IgG added, and the streptavidin gold is critical for assay optimization. The appropriate concentration of biotinylated antigen to use with strips is dependent upon the purity and sequence and a standard curve can be used to determine the relative ratio (generally between 1ng-100ng per test). A positive control line (biotin-rabbit IgG) antibody will bind to the goat anti rabbit (GAR) line on the test to ensure the assay is running appropriately.
Attogene’s Human IgG/IgM universal fluorescent lateral flow assay kit is a ready-to-use, universal test strip, which is based on the lateral flow technology that uses 655nm Emission Quantum Dot particles containing streptavidin to conveniently capture biotinylated antigens. The device is designed to easily develop qualitative or quantitative rapid test systems for detection of anti-human IgG and IgM antibody that react to the any antigen that can be biotinylated (i.e. viral antigen, autoimmune antigen) and is easily customizable providing every laboratory with the possibility to perform assay feasibility.
Formats (fluorescent broad range UV light excitation range of 300nm to 400nm, 610nm emission) Streptavidin conjugate pad):
Other Products
β-Glucan Assay Kit (Mixed Linkage)
Product Info
Document
Product Info
K-BGLU
SKU: 700004269
100 assays per kit
Content:
100 assays per kit
Shipping Temperature:
Ambient
Storage Temperature:
Short term stability: 2-8oC, Long term stability: See individual component labels
Stability:
> 2 years under recommended storage conditions
Analyte:
β-Glucan
Assay Format:
Spectrophotometer
Detection Method:
Absorbance
Wavelength (nm):
510
Signal Response:
Increase
Linear Range:
4 to 100 μg of D-glucose per assay
Limit of Detection:
0.5 g/100 g
Total Assay Time:
~ 100 min
Application examples:
Oats, barley, malt, wort, beer, food and other materials.
Method recognition:
AACC Method 32-23.01, AOAC Method 995.16, AOAC Method 992.28, CODEX Method Type II, EBC Method 3.10.1, ICC Standard No. 166 and RACI Standard Method
The Beta-Glucan test kit is suitable for the measurement and analysis of Beta-Glucan (Mixed Linkage).
For the measurement of 1,3:1,4-β-D-glucan in cereal grains, milling fractions, wort, beer and other food products.
HiDi® stands for High Discrimination of mismatches at the 3’-terminus of primers in PCR. This myPOLS Biotec enzyme family is optimized for this feature and is the first choice for applications that rely on this property such as allele-specific PCR (asPCR) that is also termed allele-specific amplification (ASA).This polymerase is also available as a full-length Taq DNA polymerase with a nuclease domain, featuring 100% compatibility with hydrolysis probes (TaqMan® probes etc.).Benchmarking with products of competitors conducted by us and others show that the HiDi® DNA polymerase family is the first choice for highly selective PCRs, such as genotyping by allele-specific PCR, HLA genotyping, analysis of single CpG methylation sites or the detection of mutations in a high background of wild-type sequences. By using HiDi® DNA polymerase, less than 10 copies of a mutation can be detected in a background of >10.000 wild-type copies straight away without any other tedious assay optimization.Several independently conducted studies show that HiDi® DNA polymerase is ideally suited for use in asPCR in numerous research areas ranging from mutation detection to genome editing. (read more) For research use and further manufacturing.In case you are aiming to use our RUO products as components or for your development of e.g. an IVD medical device, please contact us.
Casestudies: HiDi® DNA Polymerase: Applications from mutation detection to genome editing (read more)
Example Primer Design
Matching vs. mismatching nucleotide is placed at the 3′-end of the primer for best discrimination results.
Example Results – There´s no accounting for taste
Cilantro: some people love it in their food, some hate it. Here we are detecting a genomic SNP (rs72921001) in HeLa genomic DNA. This SNP is reported to be close to a number of genes coding for olfactory receptors. (Reference: Eriksson N. et al. (2012), “A genetic variant near olfactory receptor genes influences cilantro preference.”)
Considering, that only the C-allele specific primer is extended and yielding in a specific amplicon, we can conclude a genetic predisposition in disliking cilantro, as this SNP is significantly associated with detecting a soapy taste to cilantro.
Allele-specific PCRs were performed from 1 ng/µl of HeLa gDNA in the presence of a realtime dye, indicating the amplification of the C-allele specific primer only. The A-allele specific primer is discriminated, thus not amplified up to 50 cycles.
PCR products were subsequently analysed on a 2.5% agarose gel. Specific product is visualized by ethidium bromide staining at the amplicon length of 109 bp.
Document
HiDi® stands for High Discrimination of mismatches at the 3’-terminus of primers in PCR. This myPOLS Biotec enzyme family is optimized for this feature and is the first choice for applications that rely on this property such as allele-specific PCR (asPCR) that is also termed allele-specific amplification (ASA).
Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumor immunity, as PD-L1 has been shown to induce apoptosis of activated T cells or inhibit activity of cytotoxic T cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non–small-cell lung cancer, melanoma, and renal-cell cancer.
